Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Glaxo Wellcome UK Ltd., Trading as GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS
Beconase Aqueous Nasal Spray.
| Pharmaceutical Form |
|---|
|
Aqueous suspension for intranasal inhalation via metered dose atomising pump. |
Beclometasone Dipropionate 50μg (as monohydrate, micronised).
Excipient with known effect: Benzalkonium Chloride.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Beclometasone |
Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. |
| List of Excipients |
|---|
|
Avicel RC 591 (Microcrystalline Cellulose and Carboxymethylcellulose Sodium) US NF |
A 25ml amber neutral glass bottle fitted with a metering atomising pump, or a 30ml polypropylene bottle fitted with a tamper-resistant metering atomising pump. The pumps are manufactured by: Valois S.A. Le Prieure BPG, 27110 Le Neubourg, France.
Pack size: 200 Metered Spray.
Glaxo Wellcome UK Ltd., Trading as GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS
PL 10949/0104
12th April 2003
| Drug | Countries | |
|---|---|---|
| BECONASE | France, Hong Kong, Ireland, Lithuania, Mexico, New Zealand, Tunisia, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
